JESSICA HAUSLER: Open Payments
NPI 1609180314 · LATHAM, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$632 in 21 payments from 9 companies in 2025. Trend: 2023 $1,139 · 2024 $1,079 · 2025 $632
Food & beverage: $632
| Company | Payments | Amount |
|---|---|---|
| REVANCE THERAPEUTICS, INC. | 2 | $244 |
| GlaxoSmithKline, LLC. | 5 | $109 |
| Novo Nordisk Inc | 4 | $85 |
| ABBVIE INC. | 4 | $78 |
| Lilly USA, LLC | 2 | $33 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Abbott Laboratories | 1 | $19 |
Products named: DAXXIFY, TRELEGY ELLIPTA, Wegovy, QULIPTA, XIFAXAN, Sotyktu, VOQUEZNA, ZEPBOUND.
Industry payments across NY — which companies pay providers there.
